Literature DB >> 16850525

Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth.

Miriam G Jasiulionis1, Augusto D Luchessi, Andreia G Moreira, Pedro P C Souza, Ana P M Suenaga, Mariangela Correa, Carlos A S Costa, Rui Curi, Claudio M Costa-Neto.   

Abstract

The eukaryotic translation initiation factor 5A (eIF5A) undergoes a specific post-translational modification called hypusination. This modification is required for the functionality of this protein. The compound N1-guanyl-1,7-diaminoheptane (GC7) is a potent and selective inhibitor of deoxyhypusine synthase, which catalyses the first step of eIF5A hypusination process. In the present study, the effects of GC7 on cell death were investigated using two cell lines: melan-a murine melanocytes and Tm5 murine melanoma. In vitro treatment with GC7 increased by 3-fold the number of cells presenting DNA fragmentation in Tm5 cells. Exposure to GC7 also decreased viability to both cell lines. This study also describes, for the first time, the in vivo antitumour effect of GC7, as indicated by impaired melanoma growth in C57BL/6 mice. 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16850525     DOI: 10.1002/cbf.1351

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  26 in total

1.  Insulin action on protein synthesis and its association with eIF5A expression and hypusination.

Authors:  André Ricardo Gomes de Proença; Karina Danielle Pereira; Leticia Meneguello; Leticia Tamborlin; Augusto Ducati Luchessi
Journal:  Mol Biol Rep       Date:  2018-12-05       Impact factor: 2.316

2.  eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma.

Authors:  Fei Xue; Yanhui Liu; Haoyuan Chu; Yu Wen; Lei Yan; Qiang Tang; Erhui Xiao; Dongyi Zhang; Hongwei Zhang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

Review 4.  The translation factor eIF5A and human cancer.

Authors:  Michael B Mathews; John W B Hershey
Journal:  Biochim Biophys Acta       Date:  2015-05-13

Review 5.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

6.  A new non-radioactive deoxyhypusine synthase assay adaptable to high throughput screening.

Authors:  Myung Hee Park; Ajeet Mandal; Swati Mandal; Edith C Wolff
Journal:  Amino Acids       Date:  2017-08-17       Impact factor: 3.520

7.  KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.

Authors:  Ken Fujimura; Huawei Wang; Felicia Watson; Richard L Klemke
Journal:  Cancer Res       Date:  2018-01-10       Impact factor: 12.701

Review 8.  Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.

Authors:  Gregory R Kardos; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2015-09       Impact factor: 4.693

9.  Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to UVB in a melanogenesis-independent manner.

Authors:  Karl Gledhill; Lesley E Rhodes; Margaret Brownrigg; Ann K Haylett; Mojgan Masoodi; Anthony J Thody; Anna Nicolaou; Desmond J Tobin
Journal:  Pigment Cell Melanoma Res       Date:  2010-03-17       Impact factor: 4.693

10.  Targeting eIF5A Hypusination Prevents Anoxic Cell Death through Mitochondrial Silencing and Improves Kidney Transplant Outcome.

Authors:  Nicolas Melis; Isabelle Rubera; Marc Cougnon; Sébastien Giraud; Baharia Mograbi; Amine Belaid; Didier F Pisani; Stephan M Huber; Sandra Lacas-Gervais; Konstantina Fragaki; Nicolas Blondeau; Paul Vigne; Christian Frelin; Thierry Hauet; Christophe Duranton; Michel Tauc
Journal:  J Am Soc Nephrol       Date:  2016-09-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.